Dino Mustafić

March 28, 2022 Off

Xenpozyme (olipudase alfa) Approved in Japan, First and Only Approved Therapy Indicated to Treat Acid Sphingomyelinase Deficiency

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for Xenpozyme (olipudase alfa) for the treatment of adult and pediatric patients with non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD), a rare, progressive, and potentially life-threatening genetic disease.

March 28, 2022 Off

Publication of definitive end result for Vifor Pharma tender offer

By Dino Mustafić

CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of CSL Limited (ASX: CSL; USOTC: CSLLY), have announced the definitive notice of the end result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348) for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.

March 24, 2022 Off

FDA Approves Label Update for HIV Treatment Cabenuva, Making the Oral Lead-in Period Optional

By Dino Mustafić

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, has announced that the US Food and Drug Administration (FDA) approved a label update for Cabenuva (cabotegravir, rilpivirine) making the oral lead-in with cabotegravir and rilpivirine tablets optional.

March 24, 2022 Off

GenNext Technologies Announces $2.5M Arant Award to Commercialise In-Cell Protein Footprinting Instrumentation

By Dino Mustafić

GenNext Technologies, Inc., a growth-stage company providing biopharmaceutical drug discovery systems and services, has announced the receipt of a two year, Phase II SBIR grant for a project titled “In-Cell Automated Flash Oxidation (IC-AutoFox™) Protein Footprinting System.”

March 24, 2022 Off

Celonic to Become a Long-Term Partner of the Federal Republic of Germany for Vaccine Supply

By Dino Mustafić

Celonic AG has signed contract with the Federal Republic of Germany to secure the long-term supply of vaccines in Germany against Covid-19 and other pandemics. Celonic is one of five companies that the Federal Republic of Germany decided to sign contract with.

March 24, 2022 Off

New Incubator Biotope by VIB Launches to Support Biotech Startup Teams on Their Journey to Success

By Dino Mustafić

Incubator program biotope launches today to support biotech startup teams looking to impact people’s lives through innovation.

March 24, 2022 Off

Valneva Reports Loss in Y2021, Has Big Plans for 2022

By Dino Mustafić

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, has reported €73 million net loss in its audited consolidated financial results for the year ending December 31, 2021 and provided corporate updates.

March 24, 2022 Off

FDA approves Novartis’s Pluvicto for Treatment of Advanced Prostate Cancer

By Dino Mustafić

The US Food and Drug Administration (FDA) has approved Novartis’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer

March 23, 2022 Off

COVID-19 Pediatric Vaccines Successfully Met Primary Endpoints (Phase 2/3 Study in Children 6 Months to Under 6 Years)

By Dino Mustafić

Moderna, Inc. (NASDAQ:MRNA) has announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age.

March 23, 2022 Off

Kayentis Launches Fully Integrated Platform for Decentralized Clinical Trials

By Dino Mustafić

Kayentis, a global provider of eCOA and Decentralized Clinical Trial solutions, has announces the launch of a fully integrated patient-centric…